Multivariate Cox regression models for PFS and OS in patients treated with 6 cycles of eBEACOPP
| . | PFS . | OS . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Large mediastinal mass | ||||
| Yes (vs no) | 0.6 (0.3-1.1) | .08 | 0.2 (0.1-1.0) | .05 |
| Extranodal involvement | ||||
| Yes (vs no) | 0.8 (0.4-1.5) | .5 | 0.5 (0.1-2.1) | .3 |
| IPS | ||||
| 3-7 vs 0-2 | 1.2 (0.7-2.1) | .4 | 0.8 (0.3-2.2) | .7 |
| DS | ||||
| 4 (vs 1-3) | 2.4 (1.4-4.1) | .002 | 3.2 (1.3-8.4) | .02 |
| . | PFS . | OS . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Large mediastinal mass | ||||
| Yes (vs no) | 0.6 (0.3-1.1) | .08 | 0.2 (0.1-1.0) | .05 |
| Extranodal involvement | ||||
| Yes (vs no) | 0.8 (0.4-1.5) | .5 | 0.5 (0.1-2.1) | .3 |
| IPS | ||||
| 3-7 vs 0-2 | 1.2 (0.7-2.1) | .4 | 0.8 (0.3-2.2) | .7 |
| DS | ||||
| 4 (vs 1-3) | 2.4 (1.4-4.1) | .002 | 3.2 (1.3-8.4) | .02 |